Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.

Abstract

The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease (ESRD). The reasons for this and previous negative findings are discussed. In contrast, there is evidence that statins exert a nephroprotective action in less advanced chronic kidney disease (CKD). There is need for further trials to establish if patients at various stages of CKD will benefit from statin treatment in terms of both nephroprotection and reduction in vascular events.

• Authors: Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P Mikhailidis
• Journal: Current vascular pharmacology (Curr Vasc Pharmacol) Vol. 7 Issue 3 Pg. 264-6 (Jul 2009) ISSN: 1570-1611 [Print] United Arab Emirates
• PMID: 19601850 (Publication Type: Editorial, Review)

Chemical References

• Fluorobenzenes
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Pyrimidines
• Sulfonamides
• Rosuvastatin Calcium

Topics

• Cardiovascular Diseases (complications, drug therapy)
• Drug Administration Schedule
• Fluorobenzenes (administration & dosage)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage)
• Kidney Failure, Chronic (complications, drug therapy, therapy)
• Pyrimidines (administration & dosage)
• Randomized Controlled Trials as Topic
• Renal Dialysis
• Rosuvastatin Calcium
• Sulfonamides (administration & dosage)